CareDx (CDNA) Hisse Özeti
CareDx, Inc. nakil hastalarının sonuçlarını iyileştirmek ve Amerika Birleşik Devletleri'nde ve uluslararası alanda organ sağlığını ilerletmek için çözümler sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 6/6 |
| Gelecekteki Büyüme | 3/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
Risk kontrollerimizden CDNA için herhangi bir risk tespit edilmedi.
CDNA Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
ST
Fair Value from
US$21.5363.5% değerinin altında içsel indirim
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeCareDx, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$21.44 |
| 52 Haftanın En Yüksek Seviyesi | US$23.24 |
| 52 Haftanın En Düşük Seviyesi | US$10.96 |
| Beta | 2.49 |
| 1 Aylık Değişim | 21.34% |
| 3 Aylık Değişim | 10.12% |
| 1 Yıllık Değişim | 39.31% |
| 3 Yıllık Değişim | 156.46% |
| 5 Yıllık Değişim | -66.61% |
| Halka arzdan bu yana değişim | 114.40% |
Son Haberler & Güncellemeler
Analiz Güncellemesi • Apr 27
CDNA: Wider 2026 Revenue Outlook And CMS Overhang Will Drive Repricing
Analysts have raised their average price target on CareDx by $1 to $26 per share, citing a solid Q4, a wide but above-consensus 2026 revenue outlook, and a view that the stock still appears inexpensive even with ongoing uncertainty around the CMS outcome. Analyst Commentary Recent Street commentary highlights a mix of optimism around CareDx's execution and revenue outlook, alongside ongoing caution tied to policy risk.Seeking Alpha • Apr 18
CareDx: Watch For Profit-Taking After Recent Positive Preliminary Q1 Results
Summary CareDx is a leading precision medicine company specializing in transplant diagnostics, recently divesting its lab products portfolio for $170 million to focus on core testing services. CDNA demonstrates solid revenue growth and improving gross margins, but faces stiff competition from Natera, limited differentiation, and ongoing regulatory headwinds. Despite positive cash flow and a low debt/equity ratio, risks include declining R&D spending, falling book value, insider selling, and policy uncertainty that could impact revenue. I maintain a Hold rating on CDNA, viewing shares as attractive below $18, but prefer Natera for growth-oriented investors given its stronger momentum and market position. Read the full article on Seeking AlphaRecent updates
Analiz Güncellemesi • Apr 27
CDNA: Wider 2026 Revenue Outlook And CMS Overhang Will Drive Repricing
Analysts have raised their average price target on CareDx by $1 to $26 per share, citing a solid Q4, a wide but above-consensus 2026 revenue outlook, and a view that the stock still appears inexpensive even with ongoing uncertainty around the CMS outcome. Analyst Commentary Recent Street commentary highlights a mix of optimism around CareDx's execution and revenue outlook, alongside ongoing caution tied to policy risk.Seeking Alpha • Apr 18
CareDx: Watch For Profit-Taking After Recent Positive Preliminary Q1 Results
Summary CareDx is a leading precision medicine company specializing in transplant diagnostics, recently divesting its lab products portfolio for $170 million to focus on core testing services. CDNA demonstrates solid revenue growth and improving gross margins, but faces stiff competition from Natera, limited differentiation, and ongoing regulatory headwinds. Despite positive cash flow and a low debt/equity ratio, risks include declining R&D spending, falling book value, insider selling, and policy uncertainty that could impact revenue. I maintain a Hold rating on CDNA, viewing shares as attractive below $18, but prefer Natera for growth-oriented investors given its stronger momentum and market position. Read the full article on Seeking AlphaAnaliz Güncellemesi • Apr 13
CDNA: Wider 2026 Guide And CMS Overhang Will Drive Repricing
Analysts have lifted their price target on CareDx by $1 to $26, citing a solid Q4, a 2026 revenue outlook set above Street estimates, and a view that shares look inexpensive even with ongoing CMS uncertainty. Analyst Commentary Street research points to a mixed but generally constructive view on CareDx, with analysts weighing a solid recent quarter and new long term revenue guidance against ongoing policy risks and execution questions.
Analiz Güncellemesi • Mar 30
CDNA: Final MolDX LCD Decision Will Drive 2026 Outlook And Upside Potential
Narrative Update on CareDx Analysts have raised their implied fair value estimate for CareDx to $21.00 from $20.00. This reflects updated views on 2026 revenue guidance, reimbursement uncertainty and the stock's valuation relative to recent Street research commentary.Analiz Güncellemesi • Mar 16
CDNA: Wider 2026 Outlook And CMS LCD Overhang Will Drive Repricing
The analyst price target for CareDx has shifted from $23 to $24.80, as analysts balance a wider 2026 revenue outlook and recent Q4 performance against ongoing uncertainty around the final CMS LCD and its impact on long term growth. Analyst Commentary Recent Street commentary reflects a split view on CareDx, with some analysts focusing on upside tied to execution and valuation, while others emphasize uncertainty around reimbursement and longer term growth.Analiz Güncellemesi • Mar 02
CDNA: Final MolDX LCD Outcome Will Shape Appeal Despite 2026 Guidance
The analyst price target for CareDx has been raised from $18 to $20. Analysts point to a higher assumed revenue growth outlook, a slightly higher future P/E, and management's 2026 revenue guidance, while still flagging uncertainty around the final CMS LCD and its impact on longer term growth and volumes.Analiz Güncellemesi • Feb 16
CDNA: MolDX LCD Outcome Will Temper Appeal Despite Solid 2025 Guidance
Analysts have lowered their outlook on CareDx, reducing the price target to $26. They see a less compelling risk reward profile given uncertainty around the final MolDX LCD and how it could affect 2026 revenue, longer term growth, and near term test volumes.
Analiz Güncellemesi • Feb 01
CDNA: Reimbursement Outcomes Will Drive Future Upside Despite Cautious Rating
Analysts have trimmed their fair value estimate for CareDx from US$28 to US$26, citing a less compelling risk reward outlook as revenue and longer term growth now appear more closely tied to uncertain reimbursement outcomes and a much higher assumed future P/E. Analyst Commentary Recent research points to a more cautious stance on CareDx, with the key concern being how much future revenue and growth now hinge on reimbursement decisions and a higher assumed future P/E multiple.Analiz Güncellemesi • Jan 18
CDNA: MolDX LCD Uncertainty Will Restrain Appeal Despite Raised Guidance
Narrative Update on CareDx The analyst price target for CareDx has been reset to US$18.00. This reflects what analysts see as a less compelling risk reward profile, given uncertainty around future revenue tied to the final MolDX LCD and the possibility that upcoming estimates and longer term growth expectations may be too optimistic.Analiz Güncellemesi • Jan 04
CDNA: Raised Guidance And Share Buyback Will Shape Balanced Outlook
Analysts have raised their price target on CareDx from 14 dollars to 18 dollars, citing expectations for stronger revenue growth and a higher future earnings multiple, despite a modestly higher discount rate and lower projected profit margins. What's in the News Shareholder derivative lawsuits against current and former directors are moving toward a proposed global settlement, with a final approval hearing scheduled for June 30, 2026 in the U.S. District Court for the Northern District of California (shareholder litigation notice).Analiz Güncellemesi • Dec 17
CDNA: Raised Revenue Outlook And Buyback Activity Will Support Bullish Repricing
Analysts have nudged their price target on CareDx higher from around 21.83 dollars to 23.00 dollars, citing expectations for slightly faster revenue growth and a richer future valuation multiple, despite a more conservative view on long term profit margins and discount rates. What's in the News The board amended and restated company bylaws to adopt a majority voting standard for director elections, with plurality voting only in contested elections (company bylaws filing).Analiz Makalesi • Nov 29
CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 25% But Its Business Still Trails The Industry
CareDx, Inc ( NASDAQ:CDNA ) shares have continued their recent momentum with a 25% gain in the last month alone...Analiz Makalesi • Nov 12
We Believe CareDx's (NASDAQ:CDNA) Earnings Are A Poor Guide For Its Profitability
CareDx, Inc ( NASDAQ:CDNA ) recently released a strong earnings report, and the market responded by raising the share...Analiz Makalesi • Sep 19
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Those holding CareDx, Inc ( NASDAQ:CDNA ) shares would be relieved that the share price has rebounded 28% in the last...Analiz Makalesi • Aug 27
Calculating The Intrinsic Value Of CareDx, Inc (NASDAQ:CDNA)
Key Insights The projected fair value for CareDx is US$10.87 based on 2 Stage Free Cash Flow to Equity Current share...Analiz Güncellemesi • Aug 15
Rising Organ Transplant Needs Will Reshape Diagnostics Despite Challenges
CareDx’s consensus price target was reduced from $27.50 to $22.20, primarily due to heightened reimbursement risk stemming from the proposed Palmetto MolDx LCD and recent share price volatility, despite operational stability and some analysts seeing undervaluation at current levels. Analyst Commentary Ongoing uncertainty surrounding the Palmetto MolDx draft Local Coverage Determination (LCD), which proposes to limit reimbursement for certain transplant tests.Analiz Makalesi • Jul 23
The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 32%
The CareDx, Inc ( NASDAQ:CDNA ) share price has fared very poorly over the last month, falling by a substantial 32...Analiz Makalesi • May 02
Is There An Opportunity With CareDx, Inc's (NASDAQ:CDNA) 28% Undervaluation?
Key Insights The projected fair value for CareDx is US$20.92 based on 2 Stage Free Cash Flow to Equity Current share...
Yeni Analiz • Mar 24
AlloMap Testing And OPTN Project Will Expand Markets Despite Risks
CareDx's growth fueled by expanded testing services and strategic investments aims to improve margins and revenue cycle management.Seeking Alpha • Mar 13
CareDx: Some Litigation Clouds Have Cleared
Summary CareDx, Inc. has cleared up some litigation and legal challenges since I last looked at this diagnostic concern last summer. The company continues to post solid revenue growth and has a rock-solid balance sheet. FY2024 saw progress on numerous fronts, and CDNA delivered margin increases and a massive increase in adjusted EBITDA. An updated analysis around CareDx, Inc. follows in the paragraphs below. Read the full article on Seeking AlphaAnaliz Makalesi • Mar 11
Why CareDx's (NASDAQ:CDNA) Earnings Are Weaker Than They Seem
We didn't see CareDx, Inc's ( NASDAQ:CDNA ) stock surge when it reported robust earnings recently. We decided to have a...Seeking Alpha • Dec 30
CareDx: Too Risky For Me
Summary CareDx faces regulatory challenges and lacks a durable competitive advantage in a fragmented and competitive market, with no clear moat to protect its position, leading to a poor risk-reward profile. Management changes and negative employee reviews indicate potential internal instability, casting doubt on future company performance despite their innovative products. Despite strong gross margins and a solid balance sheet, CareDx's inability to turn a profit and questionable capital allocation methods make it a sell. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 05
The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 26%
CareDx, Inc ( NASDAQ:CDNA ) shareholders won't be pleased to see that the share price has had a very rough month...Seeking Alpha • Sep 29
CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics
Summary CDNA has resolved corporate instability and insurance issues, showing potential for sustainable growth with innovative transplant testing services like AlloSure, AlloMap, and HeartCare. CDNA's products are supported by scientific literature and recent Medicare coverage expansions, enhancing their market potential and revenue growth prospects. The appointment of CEO John W. Hanna provides stable leadership and strategic direction for long-term objectives. Despite ongoing legal disputes with Natera, revised processes may protect future AlloSure revenues. CDNA's valuation is high, but its expanding revenues and recent insurance coverage wins justify a "Buy" rating for investors aware of inherent biotech risks. Read the full article on Seeking AlphaAnaliz Makalesi • Aug 01
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
Despite an already strong run, CareDx, Inc ( NASDAQ:CDNA ) shares have been powering on, with a gain of 34% in the last...Seeking Alpha • Jul 15
CareDx: Benefiting From Some Certainty
Summary Today, we circle back to diagnostic testing concern CareDx, Inc for the first time in 2024. The stock has moved up some 60% since the company delivered better than expected quarterly results in early May. The company has appointed a new CEO and seen some certainty around a key patent litigation lawsuit so far this year as well. Can the rally continue, or is the stock overdue for some profit taking? An updated analysis follows in the paragraphs below. Read the full article on Seeking AlphaAnaliz Makalesi • Apr 27
Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge
CareDx, Inc ( NASDAQ:CDNA ) shares have had a horrible month, losing 28% after a relatively good period beforehand. The...Analiz Makalesi • Mar 02
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too
CareDx, Inc ( NASDAQ:CDNA ) shareholders would be excited to see that the share price has had a great month, posting a...Analiz Makalesi • Dec 27
CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry
CareDx, Inc ( NASDAQ:CDNA ) shares have continued their recent momentum with a 26% gain in the last month alone. Taking...Analiz Makalesi • Dec 27
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Despite an already strong run, CareDx, Inc ( NASDAQ:CDNA ) shares have been powering on, with a gain of 26% in the last...Hissedar Getirileri
| CDNA | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | 3.0% | 1.2% | 2.1% |
| 1Y | 39.3% | 41.9% | 30.6% |
Getiri vs. Endüstri: CDNA geçen yıl % 41.9 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: CDNA geçen yıl % 30.6 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| CDNA volatility | |
|---|---|
| CDNA Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: CDNA son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: CDNA 'nin haftalık oynaklığı ( 10% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1998 | 763 | John Hanna | caredx.com |
CareDx, Inc. nakil hastalarının sonuçlarını iyileştirmek ve Amerika Birleşik Devletleri'nde ve uluslararası alanda organ sağlığını ilerletmek için çözümler sunmaktadır. Şirket, böbrek nakli hastaları için donörden türetilmiş hücresiz DNA (dd-cfDNA) çözümü olan AlloSure Kidney; kalp nakli hastaları için gen ifadesi profilleme çözümü olan AlloMap Heart; kalp nakli hastaları için dd-cfDNA çözümü olan AlloSure Heart ve akciğer nakli hastaları için dd-cfDNA çözümü olan AlloSure Lung çözümlerini sunmaktadır. Ayrıca, bağışıklık durgunluğu, aktif hasar, akut hücresel ret ve antikor aracılı ret gibi farklı biyolojik süreçler hakkında bilgi sağlayan HeartCare; böbrek nakli biyopsi dokusunda allograft reddi ve ret türünü tanımlayan bir çözüm olan HistoMap Kidney ve akut miyeloid lösemi ve miyelodisplastik sendromlu hastalarda nüksü öngören bir izleme testi olan AlloHeme'yi de sunmaktadır.
CareDx, Inc. Temel Bilgiler Özeti
| CDNA temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$1.08b |
| Kazançlar(TTM) | -US$8.19m |
| Gelir(TTM) | US$412.82m |
2.7x
P/S Oranı-135.2x
F/K OranıCDNA aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| CDNA gelir tablosu (TTM) | |
|---|---|
| Gelir | US$412.82m |
| Gelir Maliyeti | US$128.45m |
| Brüt Kâr | US$284.37m |
| Diğer Giderler | US$292.56m |
| Kazançlar | -US$8.19m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.16 |
| Brüt Marj | 68.88% |
| Net Kâr Marjı | -1.98% |
| Borç/Özkaynak Oranı | 0% |
CDNA uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/07 03:30 |
| Gün Sonu Hisse Fiyatı | 2026/05/07 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
CareDx, Inc. 14 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |